GILD Declines 0.35% Amid Positive Clinical Trial Results and $7.8B Acquisition Announcement

Gilead Sciences, Inc. (Ticker: GILD) Market Performance Summary for February 25, 2026

Stock Price Movements

On February 25, 2026, Gilead Sciences, Inc. (GILD) experienced a notable trading session. The stock opened at $147.35 and closed at $147.12, reflecting a decrease of $0.52 or approximately -0.35% from the previous close of $147.64. During the trading day, GILD reached a high of $149.11 and a low of $146.39. The total trading volume for the day was approximately 9.15 million shares, indicating significant activity.

The intraday price fluctuations were relatively contained, with the stock moving within a range of $2.72. The highest price of $149.11 was reached shortly after the market opened, while the lowest price of $146.39 was recorded later in the session. The stock's performance reflects a slight bearish trend, which may have been influenced by external market factors and recent company announcements.

Relevant News and Announcements

Several key announcements and news items on February 25, 2026, likely influenced Gilead's stock performance:

1. Clinical Trial Results: Gilead announced the presentation of new Phase 3 trial data for its single-tablet regimen of bictegravir and lenacapavir, which maintained virological suppression in people with HIV who switched antiretroviral therapy. This data was published in The Lancet and highlighted the efficacy of Gilead's treatment options, potentially impacting investor sentiment positively. The announcement was made through a press release, which emphasized the significance of the findings for HIV treatment.
2. FDA Updates: On the same day, Gilead's experimental HIV treatment was reported to show low discontinuation rates in studies, according to a Reuters article. Such findings are crucial as they may enhance the credibility of Gilead's product pipeline and reassure investors about the company's research capabilities.
3. Acquisition of Arcellx: Earlier in the week, Gilead announced plans to acquire biotechnology company Arcellx for up to $7.8 billion. This acquisition is intended to maximize the long-term potential of Gilead's product offerings, particularly in the field of CAR T-cell therapies. While this news was released prior to February 25, it may have continued to influence market perceptions and stock performance.
4. Market Reactions: Analysts have been closely monitoring Gilead's performance following its recent earnings report, which indicated a 2% increase in total revenues for 2025. However, the company's financial forecast for 2026 was perceived as conservative, leading to mixed reactions from investors. The average price target for Gilead has been revised upward to $159.01, reflecting a positive outlook from some analysts despite the recent stock price decline.
5. CROI 2026 Conference: Gilead's participation in the Conference on Retroviruses and Opportunistic Infections (CROI) 2026, held from February 22-25 in Denver, Colorado, has been a focal point for the company. The conference provided a platform for Gilead to showcase its advancements in HIV treatment and prevention, which may have contributed to investor interest and market activity.

Conclusion

In summary, Gilead Sciences, Inc. (GILD) experienced a slight decline in stock price on February 25, 2026, closing at $147.12. The trading session was characterized by moderate fluctuations and significant trading volume. Key announcements regarding clinical trial results and the acquisition of Arcellx, along with ongoing discussions from the CROI 2026 conference, played a crucial role in shaping market perceptions. While the stock faced downward pressure, the overall outlook remains cautiously optimistic, supported by positive analyst ratings and ongoing developments in Gilead's product pipeline.